Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - The allegations state that Centene misled investors about its business prospects, particularly regarding projected revenue and enrollment rates [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a significant stock price decline of over 40% from $56.65 to $44.78 per share [3] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5] - Interested parties can sign up for notifications regarding the class action settlement or alerts on corporate wrongdoing [6]

Core Viewpoint - Centene Corporation (CNC) is expected to report a significant decline in earnings for Q2 2025, with an estimated earnings per share of 68 cents, reflecting a 71.9% decrease from the same quarter last year [1][6]. Earnings Estimates - The Zacks Consensus Estimate for revenues is projected at $43.9 billion, indicating a 10.3% growth compared to the previous year [2]. - The earnings estimate has not seen any upward revisions, with two downward movements in the past week [2]. Earnings Surprise History - Centene has beaten earnings estimates in three of the last four quarters, with an average surprise of 25.47% [3]. - The current Earnings ESP for Centene is 0.00%, and it holds a Zacks Rank of 5 (Strong Sell), suggesting a low probability of an earnings beat this time [4]. Factors Influencing Q2 Results - Premium revenues are expected to rise by 14% due to growth in the Commercial Marketplace business, with estimates for premiums at $39.9 billion, a 13.6% increase year-over-year [6][8]. - Medical costs are anticipated to surge by 17.8% year-over-year, which may negatively impact overall margins [6][12]. - Membership in the Commercial Marketplace is projected to grow by 22.7%, while Medicaid and Medicare memberships are expected to decline by 1.9% and 9.8%, respectively [9]. Revenue and Cost Projections - Service revenues are estimated at $774 million, reflecting a 7.1% decline from the previous year [10]. - The health benefits ratio (HBR) is expected to increase to 91%, indicating a deterioration of 300 basis points year-over-year [11].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation, alleging securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves Centene and certain officers and/or directors regarding potential securities fraud [2]. - Investors have until September 8, 2025, to request appointment as Lead Plaintiff if they purchased Centene securities during the Class Period [2]. Group 2: Company Performance - On July 1, 2025, Centene announced the withdrawal of its 2025 GAAP and adjusted diluted earnings per share (EPS) guidance due to market growth in 22 out of 29 states not meeting expectations [4]. - The company cited higher-than-anticipated health risks in these states affecting its risk adjustment revenue calculations [4]. Group 3: Stock Market Reaction - Following the announcement, Centene's stock price dropped by $22.87 per share, or 40.37%, closing at $33.78 per share on July 2, 2025 [5].

SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit – captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities and charges Centene and certain of Centene’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Centene class action lawsuit, ...

Core Viewpoint - Centene Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between December 12, 2024, and June 30, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Centene provided misleading statements about its enrollment and morbidity rates while concealing adverse facts [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [2] - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [2] Group 2: Investor Information - Investors who suffered losses during the relevant timeframe have until September 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Analysts forecast that Centene (CNC) will report quarterly earnings of $0.68 per share, indicating a year-over-year decline of 71.9%, while revenues are expected to reach $44.27 billion, reflecting an increase of 11.1% compared to the previous year [1]. Earnings Estimates - Over the last 30 days, there has been a downward revision of 57.3% in the consensus EPS estimate for the quarter, indicating a significant reconsideration by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are strongly linked to short-term stock price performance [3]. Revenue Projections - Analysts project 'Revenues- Premium and service revenues' to reach $40.68 billion, a year-over-year increase of 13.1% [5]. - 'Revenues- Premium' is expected to be $39.91 billion, reflecting a 13.6% increase year over year [5]. - 'Revenues- Service' is estimated at $774.23 million, indicating a decline of 7.1% from the prior year [5]. - 'Revenues- Premium tax' is anticipated to be $3.32 billion, showing a decrease of 14.2% year over year [6]. Membership Metrics - 'Membership by line of business - Medicaid' is projected at 12.89 million, down from 13.14 million in the same quarter last year [7]. - 'Membership by line of business - Medicare PDP' is expected to reach 7.89 million, up from 6.60 million a year ago [7]. - 'Membership by line of business - Medicare' is estimated at 1.03 million, compared to 1.14 million last year [8]. - 'Membership Medicaid - Traditional Medicaid' is projected at 11.31 million, down from 11.64 million in the previous year [8]. - 'Membership Medicaid - High Acuity Medicaid' is estimated at 1.58 million, slightly up from 1.50 million last year [9]. - 'Membership Commercial - Commercial Group' is expected to reach 443.35 thousand, compared to 426.40 thousand a year ago [9]. Expense Ratios - Analysts estimate the 'SG&A Expense Ratio' to be 7.8%, a decrease from 8.0% in the same quarter last year [10]. Stock Performance - Centene shares have shown a return of -48.6% over the past month, contrasting with the Zacks S&P 500 composite's +5.9% change, indicating expected underperformance in the near future [11].

Core Viewpoint - Centene Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between December 12, 2024, and June 30, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided misleading positive statements while concealing adverse facts about the company's enrollment and morbidity rates [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [2] - Following this announcement, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until September 8, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states served by Centene [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates [5]. - Following this news, Centene's stock price plummeted by $22.87 per share, a decline of over 40%, from $56.65 on July 1, 2025, to $33.78 on July 2, 2025 [5].

Core Viewpoint - Centene Corporation will release its 2025 second quarter financial results on July 25, 2025, at 6:00 a.m. ET, followed by a conference call at 8:00 a.m. ET to discuss the results [1]. Group 1: Financial Results Announcement - The financial results will be available for review on July 25, 2025, at approximately 6:00 a.m. ET [1]. - A conference call will be held at 8:00 a.m. ET on the same day to discuss the financial results [1]. Group 2: Conference Call Participation - Interested parties can join the conference call by dialing 1-877-883-0383 in the U.S. and Canada or +1-412-902-6506 from abroad, using the Elite Entry Number: 7878291 for expedited registration [2]. - The call can also be accessed via a live audio webcast on Centene's website under the Investors section [2]. Group 3: Webcast Replay Information - A replay of the webcast will be available for on-demand listening for 12 months, until July 24, 2026 [3]. - Digital audio playback will be accessible until August 1, 2025, by dialing specific numbers and entering access code 7322068 [3]. Group 4: Company Overview - Centene Corporation is a Fortune 500 company focused on providing integrated, high-quality, and cost-effective healthcare services, particularly to under-insured and uninsured individuals [4]. - The company serves over 1 in 15 individuals in the U.S., including Medicaid and Medicare members, as well as those in the Health Insurance Marketplace [4]. Group 5: Investor Relations - Centene utilizes its investor relations website to publish important information deemed material to investors [5]. - Financial and other relevant information about Centene is routinely posted and accessible on its investor relations website [5].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for alleged violations of securities laws, claiming the company made false and misleading statements regarding its growth and revenue forecasts [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between December 12, 2024, and June 30, 2025, during which investors are encouraged to contact the Schall Law Firm before September 8, 2025 [2]. - The complaint alleges that Centene misrepresented its ability to forecast growth and revenue, leading to a false impression of strong enrollment rates and low morbidity [4]. Group 2: Impact on Investors - The company's optimistic guidance was contradicted by an analysis revealing lower-than-expected enrollment and increased market morbidity, resulting in material misstatements throughout the class period [4]. - When the truth about Centene's performance became known, investors reportedly suffered damages [4].